Cardiosphere-Derived Stem Cells for Treatment of Heart Disease
Filed in archive Stem Cells on September 30, 2008
During the recently held Southern California BioMedical Council (SoCalBio or SCBC) 10th Investor Conference, biotech firm Capricor Inc presented their Cardiosphere-derived Stem Cells or CDC technology, and the multi-billion dollar market potential for heart therapies using CDC.
"CDCs are the perfect stem cells to treat heart attacks and chronic heart failure" said Foellmer [President and CEO]. " Our stem cells are easily accessible from the patient themselves, readily grown in large numbers, and have proven themselves extremely safe. Unlike embryonic stem cells, there are no ethical or moral quandaries. And unlike other adult stem cells, such as bone Marrow stem cells, our CDCs actually regrow cardiac muscle and vasculature. In short, CDCs have great potential for patients with a recent heart attack or chronic heart failure and we eagerly look forward to our imminent clinical trials."
Capricor Inc. is headquartered in Los Angeles, California, and specializes in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases. See their products currently under clinical trials.
Tags: stemcells investor biotech+investment stem+cells heart+disease HTTP/1.1+404+Not+Found ContentType:+
Vote for Cardiosphere-Derived Stem Cells for Treatment of Heart Disease:
|
Rating: 6.00 out of 4 vote(s) cast.
|
Response from:
john
(10/13/08 2:00pm)
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells


That article is here:
http://jolt.unc.edu/blog/2008/10/11/stem-cell-science-present-achievem
ent-and-future-prospects